Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged
birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular
iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®)
as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced
diagnostic imaging procedure.
Phase:
Phase 4
Details
Lead Sponsor:
GE Healthcare
Collaborators:
Bayer Duke Clinical Research Institute Guerbet/Liebel-Flarsheim